NasdaqCM:CAPR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy (DMD), and other rare disorders. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has Capricor Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CAPR's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-13.8%

CAPR

-4.0%

US Biotechs

-1.4%

US Market


1 Year Return

55.6%

CAPR

31.7%

US Biotechs

17.8%

US Market

Return vs Industry: CAPR exceeded the US Biotechs industry which returned 33.9% over the past year.

Return vs Market: CAPR exceeded the US Market which returned 18.5% over the past year.


Shareholder returns

CAPRIndustryMarket
7 Day-13.8%-4.0%-1.4%
30 Day-20.9%0.1%4.7%
90 Day-45.6%-3.5%8.2%
1 Year55.6%55.6%34.0%31.7%20.5%17.8%
3 Year-81.9%-81.9%18.7%12.8%42.2%32.7%
5 Year-89.9%-89.9%13.4%5.4%83.4%62.7%

Price Volatility Vs. Market

How volatile is Capricor Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Capricor Therapeutics undervalued compared to its fair value and its price relative to the market?

2.61x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CAPR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CAPR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CAPR is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CAPR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CAPR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CAPR is good value based on its PB Ratio (2.6x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is Capricor Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

24.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Capricor Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Capricor Therapeutics performed over the past 5 years?

13.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CAPR is currently unprofitable.

Growing Profit Margin: CAPR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CAPR is unprofitable, but has reduced losses over the past 5 years at a rate of 13.5% per year.

Accelerating Growth: Unable to compare CAPR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CAPR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: CAPR has a negative Return on Equity (-27.31%), as it is currently unprofitable.


Next Steps

Financial Health

How is Capricor Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CAPR's short term assets ($36.6M) exceed its short term liabilities ($1.9M).

Long Term Liabilities: CAPR's short term assets ($36.6M) exceed its long term liabilities ($3.6M).


Debt to Equity History and Analysis

Debt Level: CAPR's debt to equity ratio (1%) is considered satisfactory.

Reducing Debt: CAPR's debt to equity ratio has reduced from 203.6% to 1% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CAPR has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CAPR has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 7.9% each year


Next Steps

Dividend

What is Capricor Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CAPR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CAPR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CAPR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CAPR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CAPR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.7yrs

Average management tenure


CEO

Linda Marbán (57 yo)

10.75yrs

Tenure

US$228,919

Compensation

Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be ...


CEO Compensation Analysis

Compensation vs Market: Linda's total compensation ($USD228.92K) is below average for companies of similar size in the US market ($USD589.00K).

Compensation vs Earnings: Linda's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Frank Litvack
Executive Chairman of the Boardno dataUS$185.84k0.10%
$ 85.6k
Linda Marbán
Co-Founder10.75yrsUS$228.92k1.81%
$ 1.5m
Anthony Bergmann
CFO & Corporate Treasurer2.75yrsUS$252.83k0.0010%
$ 853.3
Karen Krasney
Executive VP8.58yrsUS$340.33k0.0056%
$ 4.7k
Eduardo Marbán
Co-Founder & Chairman of Scientific Advisory Boardno datano data0%
$ 0
Deborah Ascheim
Consultant1.92yrsUS$364.90kno data
Catherine Kelleher
Consultantno datano datano data

5.7yrs

Average Tenure

57yo

Average Age

Experienced Management: CAPR's management team is seasoned and experienced (5.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Frank Litvack
Executive Chairman of the Boardno dataUS$185.84k0.10%
$ 85.6k
Linda Marbán
Co-Founder10.75yrsUS$228.92k1.81%
$ 1.5m
Eduardo Marbán
Co-Founder & Chairman of Scientific Advisory Boardno datano data0%
$ 0
George Dunbar
Independent Director6.92yrsUS$14.12k0%
$ 0
Earl Collier
Independent Director6.92yrsUS$12.67k0%
$ 0
David Musket
Independent Director6.92yrsUS$24.24k0.15%
$ 125.9k
Francesco Muntoni
Member of Scientific Advisory Boardno datano datano data
Thomas Voit
Member of Scientific Advisory Boardno datano datano data
Louis Manzo
Independent Director6.92yrsUS$11.95k0.55%
$ 455.4k
Ron Victor
Member of Scientific Advisory Boardno datano datano data
Eugenio Mercuri
Member of Scientific Advisory Boardno datano datano data
Craig McDonald
Member of Scientific Advisory Boardno datano datano data

6.9yrs

Average Tenure

68.5yo

Average Age

Experienced Board: CAPR's board of directors are considered experienced (6.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 428%.


Top Shareholders

Company Information

Capricor Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Capricor Therapeutics, Inc.
  • Ticker: CAPR
  • Exchange: NasdaqCM
  • Founded: 2005
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$82.841m
  • Shares outstanding: 19.72m
  • Website: https://www.capricor.com

Number of Employees


Location

  • Capricor Therapeutics, Inc.
  • 8840 Wilshire Boulevard
  • 2nd Floor
  • Beverly Hills
  • California
  • 90211
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CAPRNasdaqCM (Nasdaq Capital Market)YesNew Common StockUSUSDNov 2013
4LN2DB (Deutsche Boerse AG)YesNew Common StockDEEURNov 2013

Biography

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duch ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 00:13
End of Day Share Price2020/10/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.